Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer
Stage III Prostate Cancer
About this trial
This is an interventional treatment trial for Stage III Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
Disease is currently controlled with androgen ablation therapy Androgen ablation is expected to continue for at least 1 year Has been treated with androgen ablation therapy for at least 1 month Stable or decreasing prostate-specific antigen (PSA) on androgen ablation therapy Stable or no visible metastatic disease on imaging Eastern Cooperative Oncology Group (ECOG) functional status of at 0 or 1
Exclusion Criteria:
Eligible for local intervention with surgery or radiation Increasing serum PSA on hormonal ablation Radiographic evidence of progression of disease on hormonal ablation Current or history of second malignancy Previously treated with chemotherapeutic agents Previous history of intermittent androgen therapy Gastrointestinal (GI) disease that impacts absorption of nutrients
Sites / Locations
Arms of the Study
Arm 1
Experimental
Treatment (omega-3 fatty acid)
Patients receive long-term omega-3 PUFA supplementation PO.